SCHEMBL5654843

SCHEMBL5654843

O=C(NCCC[C@H](NC(=O)c1cc2ccccc2o1)C(=O)O)OCc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 4/20 0.77
FOLH1 Q04609 3/20 0.57
ITGB3 P05106 2/20 0.54
ITGAV P06756 2/20 0.54
PIN1 Q13526 1/20 0.52
TAS1R3 Q7RTX0 2/20 0.52
TAS1R1 Q7RTX1 2/20 0.52
MAOB P27338 1/20 0.51
CPB1 P15086 1/20 0.51
CPB2 Q96IY4 1/20 0.51
ALDH1A1 P00352 2/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
MMP2 P08253 1/20 0.49
MMP9 P14780 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5797231 0.90 PTGER4 (0.77) PTGER4NPC1RAB9ATP53SMN1; SMN2
SCHEMBL5653780 0.90 PTGER4 (0.82) PTGER4FOLH1TAS1R3TAS1R1CPB1
SCHEMBL5653232 0.89 PTGER4 (0.93) PTGER4FOLH1TAS1R3TAS1R1CPB1
SCHEMBL5653516 0.88 PTGER4 (0.98) PTGER4FOLH1CPB1CPB2CA1
SCHEMBL5653172 0.87 PTGER4 (1.00) PTGER4FOLH1CPB1CPB2
SCHEMBL5651834 0.87 PTGER4 (1.00) PTGER4FOLH1CPB1CPB2
SCHEMBL5797447 0.86 PTGER4 (0.71) PTGER4
SCHEMBL5653729 0.85 PTGER4 (1.00) PTGER4FOLH1CPB1CPB2
SCHEMBL5654536 0.85 PTGER4 (1.00) PTGER4FOLH1CPB1CPB2
SCHEMBL5655171 0.85 PTGER4 (0.75) PTGER4TAS1R3TAS1R1CPB1CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists ASTELLAS PHARMA INC. (JP) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists PTGER4, OXER1, RXFP4 PTGER4 1/4885FOLH1 2951/4885ITGB3 4270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.